Benralizumab

Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma.


Cat. No.: EX-A15455	Purity: >98%

	Chemical structure of Benralizumab

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
10mg	1912	in-stock
25mg	2950	in-stock
50mg	4250	in-stock
100mg	get quote	in-stock
500mg	get quote	in-stock
1g	get quote	in-stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


Synonyms	MEDI-563
Synonyms 2	BIW-8405
CAS No.	1044511-01-4
Purity	>98%
Color	Colorless to light yellow
State	Liquid
Shelf Life	>3 years if stored properly
Storage	Store at 4℃
Shipping	Shipping with ice bag

Reference:	[1]. Menzies-Gow A, et al. Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial. ERJ Open Res. 2019 Sep 25;5(3). pii: 00009-2019. [2]. Kolbeck R, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010 Jun;125(6):1344-1353.e2.
CoA	CoA of Benralizumab


		Search